GW Pharmaceuticals is a Salisbury, England company who are utilizing U.S. patents to secure cannabis are a functioning medical treatment drug.
Because these U.S. patents can be used to further GW Pharma seems bizarre since, (based on two federal agencies) who deny that cannabis should be considered helpful in terms of medical treatment. Although GW Pharma maybe helping to advance the proper courses of action.
By taking each legal step towards the FDA to approve GW Pharma as the number one leading cannabis pharmaceutical company, could that mean the U.S. might see a quick turn around? Again this comes down to individuals within the federal government who choose to identify the beneficial factors cannabis proves, instead of radical forms of chemotherapy or other dangerous solutions when it comes to various cures for cancer. So far, GW Pharma has a list of medications that could treat schizophrenia, diabetes and even a form of neurological brain cancer. The treatments just mentioned are awaiting further development.
So why is there this grand fight between The British and the U.S. when it comes to medical cannabis? Well back in the 1990’s England actually understood and with a few trials saw results as to what cannabis would provide as a medicine. The U.S. decided to crack down on “The War On Drugs”… let’s call it a reapproach of the Reagan Era.
Even more bizarre, GW Pharma has acquired a $1.9 Billion who are crafting developments with medical cannabis because of patents issued from the U.S. Patent and Trademark Office.
All along the U.S. has had the right tools yet, the federal government has decided to side-step possible solutions in return to protest that cannabis will only open up a further drug epidemic.
You may be interested
Cash Crop Today Interview with CEO of Open Grow™ João MeloEditor - September 25, 2018
Open Grow™ is a company located in Portugal that is dedicated to the research and creation of automation solutions for the agricultural growing environments. Their company aims to…
Lender420 Provides Funding Solutions to Fit Your Company’s Equipment NeedsEditor - September 24, 2018
Purchasing equipment involved in the cultivation, processing, manufacturing, and distribution of the cannabinoid-derived products can be one of the most expensive costs of setting up a successful…
Elixinol Global to increase ownership in Elixinol Japan to 50.5%Editor - September 24, 2018
Public company Elixinol Global Limited (ASX: EXL; OTCQX: ELLXF), a prominent producer of industrial hemp derived CBD products announced yesterday that its wholly-owned subsidiary, EXL International Holdings,…